NCT01262261已完成3 期
A Phase 3, Six-Month, Open-Label, Re-Treatment Study of Probuphine in Opioid Addiction
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 85
- 试验地点
- 18
- 主要终点
- Number of subjects with Adverse Events (AEs) as a measure of safety
研究概览
简要总结
Probuphine (buprenorphine implant) is an investigational implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This is a 6-month, open-label, re-treatment study that will confirm the safety and efficacy of Probuphine in patients who have previously completed the 6-month PRO-806 study with either Probuphine, placebo or sublingual buprenorphine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has voluntarily provided written informed consent prior to conducting any study-related procedures
- •Completion of 24 weeks of treatment in PRO-806
- •Subject has been deemed appropriate for entry into this extension study by the investigator
- •Females of childbearing potential must be willing to use a reliable means of contraception during the entire study.
排除标准
- •An aspartate aminotransferase (AST) levels ≥ 3 X the upper limit of normal, alanine aminotransferase (ALT) levels ≥ 3 X the upper limit of normal, total bilirubin ≥ 1.5 X the upper limit of normal, or creatinine ≥ 1.5 X upper limit of normal on the screening laboratory assessments
- •A current diagnosis of chronic pain requiring opioids for treatment
- •A pregnant or lactating female
- •Current use of agents metabolized through Cytochrome P450 3A4 (CYP 3A4) such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), or protease inhibitors (e.g., ritonavir, indinavir, and saquinavir)
- •A history of coagulopathy within the past 90 days, and/or current anti-coagulant therapy such as warfarin
- •A significant medical or psychiatric symptoms, cognitive impairment, or other factors which in the opinion of the Investigator would preclude compliance with the protocol, subject safety, adequate cooperation in the study, or obtaining informed consent
- •Any current medical conditions such as severe respiratory insufficiency that may prevent the subject from safely participating in study, or any pending legal action that could prohibit participation or compliance in the study
研究组 & 干预措施
Probuphine
Experimental
patients are first inducted on sublingual buprenorphine then switched to 4 Probuphine Implants
干预措施: Probuphine (buprenorphine implant) (Drug)
结局指标
主要结局
Number of subjects with Adverse Events (AEs) as a measure of safety
时间窗: 29 weeks
AEs that occurred after the signing of the informed consent until 4 weeks after the implants have been removed were followed. Serious AEs and AEs that were designated as possibly related to study drug were followed until resolution or stabilization.
次要结局
- Pharmacokinetic analyses through plasma buprenorphine concentration in subjects as a measure of efficacy(24 weeks)
- Average daily dose of supplemental sublingual buprenorphine as a measure of efficacy(24 weeks)
- Mean total score on SOWS as a measure of efficacy(24 weeks)
- Mean total score on COWS as a measure of efficacy(24 weeks)
- Patient-rated opioid use and problems Responder Analysis as a measure of efficacy(24 weeks)
- Percent of subjects retained as a measure of efficacy(24 weeks)
- Mean subjective opioid cravings scores as a measure of efficacy(24 weeks)
- Percent of subjects reporting illicit drug use as a measure of efficacy(24 weeks)
- Physician-rated severity of opioid use and symptoms Responder Analysis as a measure of efficacy(24 weeks)
- Overall satisfaction with treatment reported on Patient Satisfaction Survey(24 weeks)
- Mean total score on Beck Depression Inventory (BDI-II) as a measure of efficacy(24 weeks)
研究者
研究点 (18)
Loading locations...
相似试验
已完成
3 期
A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid AddictionOpioid DependencyNCT01114308Titan Pharmaceuticals287
已完成
3 期
Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe PainPainNCT02634788INSYS Therapeutics Inc322
已完成
3 期
A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus ErythematosusLupus Erythematosus, SystemicNCT02504645ImmuPharma202
已完成
4 期
Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection LocationsOpioid Use DisorderNCT05704543Indivior Inc.132
已完成
3 期
Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)Opioid Use DisorderPregnancy RelatedPregnancy, High RiskPregnancy ComplicationsBuprenorphine WithdrawalNCT05790252Washington University School of Medicine7